• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Nuwellis Inc.

    5/3/24 4:13:34 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $NUWE alert in real time by email
    SC 13G 1 ea0205218-13gintra_nuwell.htm SCHEDULE 13G

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. )*

     

    Nuwellis, Inc.

     

    (Name of Issuer)

     

    Common stock, par value $0.0001 per share

     

    (Title of Class of Securities)

     

    67113Y405

     

    (CUSIP Number)

     

    April 26, 2024

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    a.☐ Rule 13d-1(b)
    b.☒ Rule 13d-1(c)
    c.☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 67113Y405

         

     

     

    1.

    Names of Reporting Persons.

     

    Mitchell P. Kopin

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ☐

    (b) ☐

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    United States of America

    Number of
    Shares

    Beneficially

    Owned by

    Each
    Reporting
    Person
    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    815,023

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    815,023

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    815,023 (see Item 4)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    4.99% (see Item 4)

    12.

    Type of Reporting Person (See Instructions)

     

    IN; HC

     

    Page 2 of 8

     

     

    CUSIP No. 67113Y405

         

     

     

    1.

    Names of Reporting Persons.

     

    Daniel B. Asher

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ☐

    (b) ☐

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    United States of America

    Number of
    Shares

    Beneficially

    Owned by

    Each
    Reporting
    Person
    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    815,023

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    815,023

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    815,023 (see Item 4)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    4.99% (see Item 4)

    12.

    Type of Reporting Person (See Instructions)

     

    IN; HC

     

    Page 3 of 8

     

     

    CUSIP No. 67113Y405

         

     

     

    1.

    Names of Reporting Persons.

     

    Intracoastal Capital LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ☐

    (b) ☐

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of
    Shares

    Beneficially

    Owned by

    Each
    Reporting
    Person
    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    815,023

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    815,023

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    815,023 (see Item 4)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    4.99% (see Item 4)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

     

    Page 4 of 8

     

     

    Item 1.

     

    (a)Name of Issuer

     

    Nuwellis, Inc. (the “Issuer”)

     

    (b)Address of Issuer’s Principal Executive Offices

     

    12988 Valley View Road

    Eden Prairie, Minnesota 55344

     

    Item 2.

     

    (a)Name of Person Filing
    (b)Address of Principal Business Office or, if none, Residence
    (c)Citizenship

     

    This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual who is a citizen of the United States of America (“Mr. Kopin”), (ii) Daniel B. Asher, an individual who is a citizen of the United States of America (“Mr. Asher”) and (iii) Intracoastal Capital LLC, a Delaware limited liability company (“Intracoastal” and together with Mr. Kopin and Mr. Asher, collectively the “Reporting Persons”).

     

    The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 1, pursuant to which the Reporting Persons have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended.

     

    The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483.

     

    The principal business office of Mr. Asher is 111 W. Jackson Boulevard, Suite 2000, Chicago, Illinois 60604.

     

    (d)Title of Class of Securities

     

    Common stock, par value $0.0001 per share, of the Issuer (the “Common Stock”).

     

    (e)CUSIP Number

     

    67113Y405

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Page 5 of 8

     

     

    Item 4.Ownership.

     

    (a) and (b):

     

    (i) Immediately following the execution of the Securities Purchase Agreement with the Issuer on April 26, 2024 (the “SPA”) (as disclosed in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on May 1, 2024), each of the Reporting Persons may have been deemed to have beneficial ownership of 754,876 shares of Common Stock, which consisted of (i) 745,000 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA and (ii) 9,876 shares of Common Stock issuable upon exercise of a warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA (“Intracoastal Warrant 1”), and all such shares of Common Stock in the aggregate represent beneficial ownership of approximately 9.99% of the Common Stock, based on (1) 6,801,443 shares of Common Stock outstanding as of March 31, 2024 as reported by the Issuer, plus (2) 745,000 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA and (3) 9,876 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1. The foregoing excludes (I) 286,792 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 because Intracoastal Warrant 1 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 9.99% of the Common Stock, (II) 1,041,668 shares of Common Stock issuable upon exercise of a second warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA (“Intracoastal Warrant 2”) because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock and (III) 29,630 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal (“Intracoastal Warrant 3”) because Intracoastal Warrant 3 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 3 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 2,112,966 shares of Common Stock.

     

    (ii) As of the close of business on May 3, 2024, each of the Reporting Persons may have been deemed to have beneficial ownership of 815,023 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2, and all such shares of Common Stock in the aggregate represent beneficial ownership of approximately 4.99% of the Common Stock, based on (1) 6,801,443 shares of Common Stock outstanding as of March 31, 2024 as reported by the Issuer, plus (2) 8,419,996 shares of Common Stock issued at the closing of the transaction contemplated by the SPA, (3) 296,668 shares of Common Stock issued to Intracoastal upon exercise of Intracoastal Warrant 1 and (4) 815,023 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2. The foregoing excludes (I) 226,645 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2 because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock and (II) 29,630 shares of Common Stock issuable upon exercise of Intracoastal Warrant 3 because Intracoastal Warrant 3 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 3 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 1,071,298 shares of Common Stock.

     

    (c)Number of shares as to which each Reporting Person has:

     

    (i)Sole power to vote or to direct the vote: 0.

     

    (ii)Shared power to vote or to direct the vote: 815,023.

     

    (iii)Sole power to dispose or to direct the disposition of 0.

     

    (iv)Shared power to dispose or to direct the disposition of 815,023.

     

    Page 6 of 8

     

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

    Page 7 of 8

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: May 3, 2024

     

      /s/ Mitchell P. Kopin
      Mitchell P. Kopin
       
      /s/ Daniel B. Asher
      Daniel B. Asher
       
      Intracoastal Capital LLC
       
      By: /s/ Mitchell P. Kopin
        Mitchell P. Kopin, Manager

     

     

    Page 8 of 8

     

    Get the next $NUWE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NUWE

    DatePrice TargetRatingAnalyst
    7/29/2024$17.00Buy
    ROTH MKM
    More analyst ratings

    $NUWE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nuwellis Completes Acquisition of Rendiatech

    MINNEAPOLIS, March 17, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the completion of its previously announced acquisition of Rendiatech, Inc., an Israeli-based developer of automated kidney function monitoring technology designed to support clinical decision-making in critically ill patients. Rendiatech has no commercial operations and was formed to acquire certain assets of RenalSense Ltd. following its bankruptcy proceedings; the Company purchased Rendiatech primarily to gain access to such assets. The purchase expands Nuwellis' capabilities across the card

    3/17/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results

    MINNEAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Recent Highlights: Fourth quarter revenue of $2.4 million, a 4% increase compared to the prior-year quarter and 9% increase sequentially.208% increase in U.S. console sales in Q4 versus prior year quarter.Heart Failure revenue increased 48% and Pediatrics increased 16% year-over-year in Q4.Gross margin of 68.2% in Q4, compared to 58.4% in the prior-year quarter.Closed a $5.0 million private p

    3/10/26 8:15:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Strategy to Advance Pediatric and Cardiorenal Strategy

    MINNEAPOLIS, March 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Stuart L. Goldstein, MD, FASN as Director of Clinical Strategy. Dr. Goldstein is internationally recognized as a pioneer in pediatric nephrology and critical care medicine. He serves as Director of the Center for Acute Care Nephrology, holds the Clark D. West Endowed Chair in Pediatric Nephrology at Cincinnati Children's Hospital Medical Center and is Professor of Pediatrics at the University of Cincinnati College of Medicine. His work has helped define the modern understand

    3/5/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NUWE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Emerson Martin J

    3 - Nuwellis, Inc. (0001506492) (Issuer)

    3/18/26 4:26:10 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by new insider Mcdonald David

    3 - Nuwellis, Inc. (0001506492) (Issuer)

    3/2/26 4:08:18 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by new insider Schultz Carisa

    3 - Nuwellis, Inc. (0001506492) (Issuer)

    2/12/26 4:15:30 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NUWE
    SEC Filings

    View All

    Nuwellis Inc. filed SEC Form 8-K: Other Events

    8-K - Nuwellis, Inc. (0001506492) (Filer)

    3/17/26 9:13:10 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-K filed by Nuwellis Inc.

    10-K - Nuwellis, Inc. (0001506492) (Filer)

    3/11/26 5:24:35 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Nuwellis, Inc. (0001506492) (Filer)

    3/10/26 4:02:58 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NUWE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Nuwellis with a new price target

    ROTH MKM initiated coverage of Nuwellis with a rating of Buy and set a new price target of $17.00

    7/29/24 7:42:07 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NUWE
    Financials

    Live finance-specific insights

    View All

    Nuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results

    MINNEAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Recent Highlights: Fourth quarter revenue of $2.4 million, a 4% increase compared to the prior-year quarter and 9% increase sequentially.208% increase in U.S. console sales in Q4 versus prior year quarter.Heart Failure revenue increased 48% and Pediatrics increased 16% year-over-year in Q4.Gross margin of 68.2% in Q4, compared to 58.4% in the prior-year quarter.Closed a $5.0 million private p

    3/10/26 8:15:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026

    MINNEAPOLIS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it will release financial results for the fourth quarter and full year 2025 on March 10, 2026. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-800-343-4885 (U.S) or 1-203-518-9851 (international) and using the conference ID: N

    2/24/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis, Inc. To Report Third Quarter 2025 Financial Results on November 12, 2025

    MINNEAPOLIS, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardio-renal conditions, addressing the critical interplay between the heart and kidneys, today announced that it will release financial results for the third quarter 2025 on November 12, 2025. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-800-274-8461 (U.S) or 1-203-51

    10/23/25 9:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NUWE
    Leadership Updates

    Live Leadership Updates

    View All

    Nuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Strategy to Advance Pediatric and Cardiorenal Strategy

    MINNEAPOLIS, March 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Stuart L. Goldstein, MD, FASN as Director of Clinical Strategy. Dr. Goldstein is internationally recognized as a pioneer in pediatric nephrology and critical care medicine. He serves as Director of the Center for Acute Care Nephrology, holds the Clark D. West Endowed Chair in Pediatric Nephrology at Cincinnati Children's Hospital Medical Center and is Professor of Pediatrics at the University of Cincinnati College of Medicine. His work has helped define the modern understand

    3/5/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of Directors

    MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The appointments strengthen the Company's board with complementary expertise in public company leadership, capital markets, and medical device commercialization. "These appointments reflect our continued focus on operational discipline and long-term value creation," said John Erb, President and CEO of Nuwellis. "Marty has led multiple medical device organizations through scali

    2/26/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Appoints Carisa Schultz as Chief Financial Officer

    MINNEAPOLIS, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE) a medical technology company focused on advancing precision cardiorenal care, today announced the appointment of Carisa Schultz as Chief Financial Officer, effective February 2, 2026. Ms. Schultz brings extensive healthcare and public company finance leadership experience, most recently serving as Vice President of Finance at NeueHealth (formerly Bright Health Group), a healthcare company previously listed on the New York Stock Exchange. In that role, she led enterprise finance, treasury, and corporate development activities. During her tenure at NeueHealth, she also held progressive leadership roles including A

    1/30/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NUWE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Nuwellis Inc.

    SC 13G - Nuwellis, Inc. (0001506492) (Subject)

    8/30/24 4:11:06 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Nuwellis Inc.

    SC 13G - Nuwellis, Inc. (0001506492) (Subject)

    8/2/24 4:12:11 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Nuwellis Inc.

    SC 13G - Nuwellis, Inc. (0001506492) (Subject)

    5/6/24 4:01:02 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care